Document is current

Article History

Received: 27 March 2026

Accepted: 20 June 2026

First Online: 10 July 2026

Declarations

:

: All patients provided written consent and the ethical committee of each participating center approved study design before start of data collection.

: Not applicable.

: The authors declare no competing interests.

: The author(s) meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE).

: This was a collaborative research study where Boehringer Ingelheim was involved in the design, analysis or interpretation of the results but was not the regulatory sponsor.

: Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to Boehringer Ingelheim substances, as well as intellectual property considerations.

: Physicians involved in this study are involved in multiple interactions with pharmaceutical/biotechnology companies, e.g., consulting fees, honoraria for lectures/presentations, support for attending meetings and/or travel, research funding.

: CD received honoraria for lecturing, consulting and travel expenses for attending meetings from Novartis, GSK, Medac, AstraZeneca, AlfaSigma, Johnson&Johnson, Sanofi, Lilly, Amgen, AbbVie, Kyverna, Pfizer and Deutsche Rheuma-Liga.

: PK has received honoraria or travel support from Abbvie, Alfasigma, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers-Squibb, Chugai, GlaxoSmithKline, Janssen-Cilag, Lilly, Novartis, Pfizer, and Sanofi, all unrelated to this paper.

: MG and MA are employees of Boehringer-Ingelheim.

: P. M. reports lecture fees received from Boehringer Ingelheim Pharma GmbH & Co., Janssen Cilag GmbH, ECM GmbH, AEMH e.V, Leo Pharma GmbH and adboard fees received from Almirall Hermal GmbH, Boehringer Ingelheim Pharma GmbH & Co.

: JHWD has received grants or holds contracts from: AbbVie, Anamar, Argenx, ARXX, BMS, Bayer Pharma, Boehringer Ingelheim, Cantargia, Celgene, CSL Behring, ExoTherapeutics, Galapagos, GSK, Inventiva, Kiniksa, Lassen, Novartis, Sanofi-Aventis, RedX and UCB; consulting fees from: AbbVie, Active Biotech, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, Genentech, GSK, Inventiva, Janssen, Novartis, Pfizer, Roche and UCB; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from: AbbVie, Active Biotech, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, Genentech, GSK, Inventiva, Janssen, Novartis, Pfizer, Roche and UCB; Payment for expert testimony from: AbbVie, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Cantargia, Celgene, Galapagos, Genentech, GSK, Inventiva, Janssen, Novartis, Pfizer, Roche and UCB; Support for attending meetings and/or travel from: AbbVie, SOBI; Stock or stock options from: 4D Science; FibroCure; Receipt of equipment, materials, drugs, medical writing, gifts or other services from: Boehringer Ingelheim.

: AHG has received honoraria for presentations from Boehringer Ingelheim and AbbVie.

: The other authors did not declare any conflict of interest.